Integrins in cancer: biological implications and therapeutic opportunities
Publication type: Journal Article
Publication date: 2010-01-01
scimago Q1
wos Q1
SJR: 24.378
CiteScore: 103.8
Impact factor: 66.8
ISSN: 1474175X, 14741768
DOI:
10.1038/nrc2748
PubMed ID:
20029421
General Environmental Science
General Earth and Planetary Sciences
Abstract
The integrins regulate a diverse array of cellular functions that are crucial to the initiation, progression and metastasis of solid tumours. This Review discusses the exciting developments in targeting integrins, including the recent initiation of a Phase III trial for an integrin antagonist in patients with glioblastoma. The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
10
20
30
40
50
60
70
80
|
|
|
Cancers
79 publications, 2.61%
|
|
|
Oncotarget
66 publications, 2.18%
|
|
|
Scientific Reports
53 publications, 1.75%
|
|
|
International Journal of Molecular Sciences
51 publications, 1.68%
|
|
|
PLoS ONE
49 publications, 1.62%
|
|
|
Frontiers in Oncology
43 publications, 1.42%
|
|
|
Oncogene
35 publications, 1.16%
|
|
|
Journal of Controlled Release
32 publications, 1.06%
|
|
|
Cancer Research
32 publications, 1.06%
|
|
|
Cancer Letters
24 publications, 0.79%
|
|
|
Pharmaceutics
23 publications, 0.76%
|
|
|
Bioconjugate Chemistry
23 publications, 0.76%
|
|
|
Advanced Drug Delivery Reviews
22 publications, 0.73%
|
|
|
Molecular Pharmaceutics
22 publications, 0.73%
|
|
|
Nature Communications
21 publications, 0.69%
|
|
|
Biomaterials
21 publications, 0.69%
|
|
|
Frontiers in Cell and Developmental Biology
20 publications, 0.66%
|
|
|
Journal of Biological Chemistry
19 publications, 0.63%
|
|
|
Cells
18 publications, 0.59%
|
|
|
Angewandte Chemie - International Edition
17 publications, 0.56%
|
|
|
Angewandte Chemie
17 publications, 0.56%
|
|
|
Journal of Medicinal Chemistry
16 publications, 0.53%
|
|
|
Experimental Cell Research
16 publications, 0.53%
|
|
|
Molecular Cancer Therapeutics
16 publications, 0.53%
|
|
|
Journal of Cell Science
15 publications, 0.5%
|
|
|
Biochemical and Biophysical Research Communications
15 publications, 0.5%
|
|
|
International Journal of Cancer
15 publications, 0.5%
|
|
|
ACS Nano
14 publications, 0.46%
|
|
|
Journal of Materials Chemistry B
14 publications, 0.46%
|
|
|
10
20
30
40
50
60
70
80
|
Publishers
|
100
200
300
400
500
600
700
|
|
|
Elsevier
637 publications, 21.04%
|
|
|
Springer Nature
549 publications, 18.14%
|
|
|
Wiley
312 publications, 10.31%
|
|
|
MDPI
263 publications, 8.69%
|
|
|
American Chemical Society (ACS)
166 publications, 5.48%
|
|
|
Frontiers Media S.A.
111 publications, 3.67%
|
|
|
Taylor & Francis
95 publications, 3.14%
|
|
|
Royal Society of Chemistry (RSC)
90 publications, 2.97%
|
|
|
Impact Journals
69 publications, 2.28%
|
|
|
American Association for Cancer Research (AACR)
69 publications, 2.28%
|
|
|
Public Library of Science (PLoS)
53 publications, 1.75%
|
|
|
Cold Spring Harbor Laboratory
44 publications, 1.45%
|
|
|
Spandidos Publications
40 publications, 1.32%
|
|
|
Hindawi Limited
36 publications, 1.19%
|
|
|
Oxford University Press
32 publications, 1.06%
|
|
|
SAGE
27 publications, 0.89%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
24 publications, 0.79%
|
|
|
American Society for Biochemistry and Molecular Biology
21 publications, 0.69%
|
|
|
The Company of Biologists
20 publications, 0.66%
|
|
|
Bentham Science Publishers Ltd.
19 publications, 0.63%
|
|
|
Mary Ann Liebert
17 publications, 0.56%
|
|
|
American Association for the Advancement of Science (AAAS)
16 publications, 0.53%
|
|
|
American Society for Clinical Investigation
12 publications, 0.4%
|
|
|
Rockefeller University Press
12 publications, 0.4%
|
|
|
Society of Nuclear Medicine
11 publications, 0.36%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
11 publications, 0.36%
|
|
|
Walter de Gruyter
9 publications, 0.3%
|
|
|
American Physiological Society
9 publications, 0.3%
|
|
|
Bioscientifica
8 publications, 0.26%
|
|
|
100
200
300
400
500
600
700
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
3k
Total citations:
3029
Citations from 2024:
348
(11%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Desgrosellier J. S., Cheresh D. A. Integrins in cancer: biological implications and therapeutic opportunities // Nature Reviews Cancer. 2010. Vol. 10. No. 1. pp. 9-22.
GOST all authors (up to 50)
Copy
Desgrosellier J. S., Cheresh D. A. Integrins in cancer: biological implications and therapeutic opportunities // Nature Reviews Cancer. 2010. Vol. 10. No. 1. pp. 9-22.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/nrc2748
UR - https://doi.org/10.1038/nrc2748
TI - Integrins in cancer: biological implications and therapeutic opportunities
T2 - Nature Reviews Cancer
AU - Desgrosellier, Jay S
AU - Cheresh, David A
PY - 2010
DA - 2010/01/01
PB - Springer Nature
SP - 9-22
IS - 1
VL - 10
PMID - 20029421
SN - 1474-175X
SN - 1474-1768
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2010_Desgrosellier,
author = {Jay S Desgrosellier and David A Cheresh},
title = {Integrins in cancer: biological implications and therapeutic opportunities},
journal = {Nature Reviews Cancer},
year = {2010},
volume = {10},
publisher = {Springer Nature},
month = {jan},
url = {https://doi.org/10.1038/nrc2748},
number = {1},
pages = {9--22},
doi = {10.1038/nrc2748}
}
Cite this
MLA
Copy
Desgrosellier, Jay S., and David A Cheresh. “Integrins in cancer: biological implications and therapeutic opportunities.” Nature Reviews Cancer, vol. 10, no. 1, Jan. 2010, pp. 9-22. https://doi.org/10.1038/nrc2748.